Skip to content

Study · Animal study (in vivo) · mouse · 2025

2 results

Targeting ANT1 to regulate PINK1/Parkin-mediated mitophagy is an effective treatment of trauma-induced tendon heterotopic ossification.

Li G, Li T, Deng Y, Deng X, Chen C, Yu B, Zhang K

Journal of orthopaedic translation26 Aug 2025Cited by 1 (Europe PMC)

PMID41542093 (opens in a new tab)PMCIDPMC12799515 (opens in a new tab)DOI10.1016/j.jot.2025.08.002 (opens in a new tab)PepBankPUB-41542093
Read at sourcePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    Elamipretide, a drug targeting ANT1, showed significant efficacy in treating tendon heterotopic ossification in mouse and human cell and tissue tests.

    In plain wordsIn mouse and human cell and tissue tests, elamipretide worked against abnormal bone growth in injured tendon.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Direction not reportedEfficacy in treating heterotopic ossification
    Study

    mouse and humann: not reported in source

    Outcome group
    Tendon and ligament healing · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Elamipretide, a targeted drug for ANT1, showed significant efficacy in treating HO.
    1 context sentence
    Summary · context
    Its therapeutic efficacy on tendon ossification was validated using mouse cells, tissues, and human cells.
  2. 02LabIn vitro (cells)Mechanism

    Computer virtual screening and experimental verification identified elamipretide as a targeted drug for ANT1.

    In plain wordsComputer screening and lab tests identified elamipretide as a drug that acts on ANT1.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableANT1 as target of elamipretide
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, elamipretide was identified as a potential targeted drug for ANT1 through computer virtual screening and experimental verification.
    1 context sentence
    Summary · context
    Its therapeutic efficacy on tendon ossification was validated using mouse cells, tissues, and human cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.